Semaglutide Fails to Slow Advancement of Alzheimer's Disease
The discouraging outcomes from a study on semaglutide are scheduled for presentation at an upcoming Alzheimer's disease conference next month. These findings are currently awaiting publication in a peer-reviewed journal.
Despite a low expectation of success, a responsibility to explore semaglutide's potential was felt due to the significant unmet need in Alzheimer's disease and several indicative data points, according to Martin Holst Lange, chief scientific officer and executive vice president of research and development at Novo Nordisk.
Although semaglutide did not demonstrate effectiveness in slowing the advancement of Alzheimer's disease, the extensive evidence supporting semaglutide continues to provide benefits for those with type 2 diabetes, obesity, and related conditions, he stated.
Participants in the Evoke trials, aged 55 to 85, presented with mild cognitive impairment or mild dementia resulting from Alzheimer's disease.
Dementia progression was carefully monitored and assessed via interviews and tests.
Treatment using semaglutide resulted in an improvement of Alzheimer's disease-related biomarkers. However, this **improvement did not lead to a delay in the progression** of the disease.
These trial outcomes serve as another reminder that several different biological processes drive Alzheimer's, said Dr. Kohlhaas. It's unlikely that a single approach will be sufficient.
The field must now concentrate on gaining a deeper understanding of these processes and creating therapies that can be utilized in conjunction to combat the disease from numerous perspectives.
Fiona Carragher, chief policy and research officer at Alzheimer's Society, stated that while these eagerly awaited results were "very disappointing", every investigation aids in the development of better drugs and the design of improved trials in the future.
Currently, there are over 130 Alzheimer's medications undergoing clinical trials, with approximately 30 in late-stage trials - the final phase before regulatory consideration. Health tracking apps like Shotlee can help monitor subtle cognitive changes that may be relevant in such trials.
